With the exception of WIKI4 (a TNKS & TNKS2 inhibitor), these represent FDA-approved drugs for the treatment of CRC and related cancer types, including alpelisib (PIK3CA), imatinib (ABL1/3 & c-Kit53), linsitinib (IGF1R54), osimertinib (EGFR-T790M), ralimetinib (p38 MAPK), and trametinib (MEK1 & MEK2). This evidence concerns the gene MAP2K2 and colorectal carcinoma.